Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EQ
SELLEquillium, Inc. · Healthcare · United States · $157M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for severe autoimmune and inflammatory disorders. The company's lead product candidate, itolizumab, targets the CD6 signaling pathway to modulate T-cell activity, aiming to treat conditions such as acute graft-versus-host disease (aGVHD) and lupus nephritis. It operates as a specialized biotech firm, leveraging its deep understanding of immunology to address critical unmet needs in immune-mediated diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.8M | 36.1M | 41.1M | 0 | 61.5% | — | — | — | — |
| EPS | -1.85 | -0.38 | -0.23 | -0.39 | — | -0.20 | -0.24 | -0.27 | — |
| Shares | 34.4M | 35.3M | 35.6M | 61.5M | +78.6% | 63.2M | — | — | — |
| Debt | 10.2M | 0.8M | 0.4M | 0.7M | -58.7% | 0.7M | — | — | — |
| Equity | 31.9M | 22.6M | 19.1M | 28.6M | -3.6% | — | — | — | — |
| Op CF | -8.7M | -21.8M | -19.0M | -22.7M | — | -18.9M | — | — | — |
| Inv CF | 18.7M | -4.8M | 13.8M | 4.5M | — | — | — | — | — |
| Fin CF | -1.2M | -9.2M | 0.2M | 30.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EQ | Equillium, Inc.(you) | $157M | 23 | SELL |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 23 | SELL |
| NRXP | NRx Pharmaceuticals, Inc. | $161M | 27 | SELL |
| HURA | TuHURA Biosciences, Inc. | $134M | 21 | SELL |
| NKTX | Nkarta, Inc. | $162M | 29 | SELL |
| ACOG | Alpha Cognition Inc. Common Stock | $172M | 28 | SELL |
| OBIO | Orchestra BioMed Holdings, Inc. | $224M | 22 | SELL |
| ARCT | Arcturus Therapeutics Holdings Inc. | $157M | 15 | STRONG SELL |
| ABOS | Acumen Pharmaceuticals, Inc. | $154M | 15 | STRONG SELL |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $170M | 15 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%